Valores de la gasometría arterial en pacientes embarazadas con preeclampsia severa / Arterial blood gas parameters in pregnant patients with severe preeclampsia

Resumen OBJETIVO: Determinar e interpretar los valores de la gasometría arterial en pacientes embarazadas con preeclampsia severa. MATERIALES Y MÉTODOS: Estudio observacional, transversal, retrospectivo y descriptivo llevado a cabo en pacientes con más o menos 20 semanas de embarazo y diagnóstico establecido de preeclampsia severa atendidas en la unidad de cuidados intensivos entre el 1 de julio y el 31 de diciembre del 2019. Los datos generales, la condición obstétrica, los estudios de laboratorio clínico y los valores de la gasometría arterial se documentaron conforme a lo registrado en los expedientes clínicos. Se utilizó estadística descriptiva y los datos se procesaron en el programa SPSS versión 20. RESULTADOS: Se estudiaron 30 pacientes con media de edad de 31.6 ± 6.85 años, mediana de paridad 1, todas con feto único de 33.89 ± 3.43 semanas y residencia en la Ciudad de México. Los valores de la gasometría arterial fueron: pH 7.41 ± 0.08, presión parcial de dióxido de carbono 25.51 ± 6.12 mmHg, presión parcial de oxígeno 85.24 ± 41.81 mmHg, hematocrito 33.86 ± 7.51%, ión carbonato 16.95 ± 5.13 mmol/L, patrón de bicarbonato estandarizado 19.04 ± 2.50 mmol/L, gases de efecto invernadero 16.94 ± 2.51 mmHg, exceso de base del fluido extracelular -7.72 ± 5.60 mmol/L, BE (B) -7.36 ± 3.07 mmol/L, porcentaje de saturación de oxígeno 93 ± 8.29, hemoglobina total en la gasometría arterial 10.64 ± 2.36 g/dL, gradiente alvéolo-arterial de oxígeno 49.43 ± 10.98 mmHg, presión parcial de oxígeno 140.43 ± 106.93 mmHg, concentraciones de dióxido de carbono 0.79 ± 0.28 mmHg e Índice respiratorio 0.95 ± 2.57. CONCLUSIONES: Los resultados corresponden a un patrón gasométrico de acidosis metabólica compensada.

Abstract OBJECTIVE: To determine and interpret arterial blood gas values in pregnant patients with severe preeclampsia. MATERIALS AND METHODS: study carry out in a series of 30 patients with a pregnancy ≥ 20 weeks and an established diagnosis of SP admitted to the Intensive Care Unit from July 1 to December 31, 2019, in whom arterial blood gases are part of the routine studies upon admission to the ICU. Patients with recurrence of preeclampsia, eclampsia and HELLP syndrome or with metabolic, respiratory, cardiological and renal morbidities affecting arterial blood gas values were excluded. The general data, obstetric condition, clinical laboratory and arterial blood gas values were documented from the clinical records. Statistical analysis: descriptive statistics were used with the statistical package SPSS version 20. RESULTS: Thirty patients were studied, with a mean age of mean age 31.6 ± 6.85 years, median parity 1, all with a single product of 33.89±3.43 weeks and residence in Mexico City 31.37 ± 7 years. Arterial blood gas values were: pH 7.41 ± 0.08, PCO2 25.51 ± 6.12 mmHg, PO2 85.24 ± 41.81 mmHg, Hct 33.86 ± 7.51%, HCO3- 16.95 ± 5.13 mmol/L, HCO3- std 19.04 ± 2.50 mmol/L, TCO2 16.94 ± 2.51 mmHg, BE ecf -7.72 ± 5.60 mmol/L, BE (B) -7.36 ± 3.07 mmol/L, SO2c% 93 ± 8.29%, THbc 10.64 ± 2.36 g/dL, Aa DO2 49.43 ± 10.98 mmHg, pAO2 140.43 ± 106.93 mmHg, PaO2/PAO2 0.79 ± 0.28 mmHg and Respiratory Index 0.95 ± 2.57. CONCLUSIONS: The results correspond to a gasometric pattern of compensated metabolic acidosis.

Cuidados críticos en neumonía por virus SARS-CoV-2 durante el embarazo. Reporte de un caso / Critical care in SARS-CoV-2 virus pneumonia during pregnancy. Report a case

Resumen ANTECEDENTES: La pandemia mundial de SARS-CoV-2 también afecta a las embarazadas. Los casos más graves ameritan hospitalización y tratamiento en una sala de cuidados intensivos. CASO CLÍNICO: Paciente de 30 años y embarazo con feto único, de 33 semanas, con antecedentes de fibromialgia, un aborto y miomatosis uterina. La paciente negó el contacto con personas sospechosas o infectadas por el virus SARS-CoV-2. El cuadro clínico se inició con infección de las vías respiratorias superiores que evolucionó a neumonía con prueba PCR positiva para COVID-19 a partir del exudado naso-faríngeo, que condicionó el síndrome de insuficiencia respiratoria aguda severa, tratada con asistencia mecánica ventilatoria durante16 días en la unidad de cuidados intensivos. En el trascurso de la hospitalización se complicó con neumotórax bilateral y urosepsis por Candida tropicalis. La paciente superó la enfermedad viral, las complicaciones de la ventilación y la infección urinaria oportunista.

Abstract BACKGROUND: The worldwide SARS-CoV-2 pandemic also affects pregnant women. The most severe cases require hospitalization and treatment in an intensive care unit. CLINICAL CASE: A 30-year-old woman with a 33-week singleton pregnancy and a history of fibromyalgia, one miscarriage and uterine myomatosis. The patient denied contact with persons suspected or infected with SARS-CoV-2 virus. The clinical picture began with upper respiratory tract infection that progressed to pneumonia with positive PCR test for COVID-19 from nasopharyngeal exudate, which led to severe acute respiratory failure syndrome, treated with mechanical ventilation for 16 days in the Intensive Care Unit. During hospitalization, she was complicated with bilateral pneumothorax and urosepsis due to Candida tropicalis. The patient overcame the viral disease, ventilatory complications and the opportunistic urinary tract infection.

High glucose induces O-GlcNAc glycosylation of the vitamin D receptor (VDR) in THP1 cells and in human macrophages derived from monocytes.

Chronic hyperglycemia increases the carbon flux through the hexosamine pathway, allowing the accumulation of UDP-GlcNAc. UDP-GlcNAc is the sugar donor for the enzyme-mediated protein glycosylation event known as OGlcNAcylation. This posttranslational modification targets several transcription factors implicated in glucose toxicity, insulin resistance, and diabetes. Vitamin D plays an important role in glucose homeostasis and insulin secretion through transcriptional mechanisms mediated by its receptor (VDR). Vitamin D deficiency has been associated with higher susceptibility to bacterial diseases in diabetic patients. However, it has not been explored whether VDR is subject to OGlcNAcylation or whether high glucose affects its transcriptional or biological activities. The aim of this study was to evaluate the effect of hyperglycemia on VDR OGlcNAcylation and its effects on vitamin D-mediated transcription. We predicted potential OGlcNAcylation sites using free software. Our results showed that hyperglycemia (30 mM) induces the OGlcNAcylation of VDR in THP1 cells and in human macrophages derived from monocytes (MDM). This condition did not hamper the vitamin D-dependent activation of LL-37 gene expression, and even did not impair the macrophage bactericidal activity. Our study provides new insight into vitamin D receptor posttranslational modification that may have relevance on the physiological responses of long-term hyperglycemia.

High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes.

BACKGROUND: CD33 is a membrane receptor containing a lectin domain and a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) that is able to inhibit cytokine production. CD33 is expressed by monocytes, and reduced expression of CD33 correlates with augmented production of inflammatory cytokines, such as IL-1ß, TNF-α, and IL-8. However, the role of CD33 in the inflammation associated with hyperglycemia and diabetes is unknown. Therefore, we studied CD33 expression and inflammatory cytokine secretion in freshly isolated monocytes from patients with type 2 diabetes. To evaluate the effects of hyperglycemia, monocytes from healthy donors were cultured with different glucose concentrations (15-50 mmol/l D-glucose), and CD33 expression and inflammatory cytokine production were assessed. The expression of suppressor of cytokine signaling protein-3 (SOCS-3) and the generation of reactive oxygen species (ROS) were also evaluated to address the cellular mechanisms involved in the down-regulation of CD33. RESULTS: CD33 expression was significantly decreased in monocytes from patients with type 2 diabetes, and higher levels of TNF-α, IL-8 and IL-12p70 were detected in the plasma of patients compared to healthy donors. Under high glucose conditions, CD33 protein and mRNA expression was significantly decreased, whereas spontaneous TNF-α secretion and SOCS-3 mRNA expression were increased in monocytes from healthy donors. Furthermore, the down-regulation of CD33 and increase in TNF-α production were prevented when monocytes were treated with the antioxidant α-tocopherol and cultured under high glucose conditions. CONCLUSION: Our results suggest that hyperglycemia down-regulates CD33 expression and triggers the spontaneous secretion of TNF-α by peripheral monocytes. This phenomenon involves the generation of ROS and the up-regulation of SOCS-3. These observations support the importance of blood glucose control for maintaining innate immune function and suggest the participation of CD33 in the inflammatory profile associated with type 2 diabetes.

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

BACKGROUND: Pioglitazone and glimepiride improve glycemic control in patients with type 2 diabetes mellitus by different mechanisms. Pioglitazone is a thiazolidinedione that reduces insulin resistance, and glimepiride is a sulfonylurea insulin secretagogue. OBJECTIVE: The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year. METHODS: This was a multicenter, 52-week, double-blind, parallel-group trial. Patients were randomized to receive monotherapy with either glimepiride (2 mg QD initially) or pioglitazone (15 mg QD initially). Doses were titrated (maximal doses: pioglitazone 45 mg, glimepiride 8 mg) to achieve glycemic targets (fasting blood glucose < or =7 mmol/L and 1-hour postprandial blood glucose < or =10 mmol/L). Insulin sensitivity (primary end point) was evaluated in terms of the Homeostasis Model Assessment for Insulin Sensitivity (HOMA-S), the Quantitative Insulin Sensitivity Check Index (QUICKI), and fasting serum insulin (FSI) concentrations. Glycemic control was evaluated in terms of glycosylated hemoglobin (HbA(1c)) values and fasting plasma glucose (FPG) concentrations. Patients were encouraged to maintain their individual diet and exercise regimens throughout the study. RESULTS: Two hundred forty-four patients (125 women, 119 men; all but 1 Hispanic) were randomized to receive pioglitazone (n = 121) or glimepiride (n = 123). In the intent-to-treat sample, pioglitazone and glimepirede produced comparable reductions in HbA(1c) from baseline to the end of the study (-0.78% and -0.68%, respectively). The pioglitazone group had significantly higher HbA(1c) values compared with the glimepiride group after 12 weeks of therapy (8.66% vs 7.80%; P = 0.007) but had significantly lower values after 52 weeks (7.46% vs 7.77%; P = 0.027). Pioglitazone significantly reduced FPG compared with glimepiride (-0.6 vs 0.6 mmol/L; P = 0.01). Pioglitazone therapy was associated with significant increases in insulin sensitivity (reduced insulin resistance), whereas glimepiride had no effect. HOMA-S values changed 18.0% for pioglitazone and -7.9% for glimepiride (P < 0.001), QUICKI values changed a respective 0.013 and -0.007 (P < 0.001), and FSI values were -21.1 and 15.1 pmol/L (P< 0.001). Both drugs were well tolerated, with pioglitazone associated with more peripheral edema (number of treatment-emergent cases: 35/121[28.9%] vs 17/123 [13.8%]; P = 0.005) and fewer hypoglycemic episodes (19 [15.7%] vs 38 [30.9%]; P = 0.024). The incidence of weight gain was not significantly different between treatment groups. CONCLUSIONS: These data suggest that long-term treatment with pioglitazone enhances insulin sensitivity relative to glimepiride in Mexican patients with type 2 diabetes and that pioglitazone may have a more sustained antihyperglycemic effect.

Tuberculosis. Diagnóstico postmortem y su relación con el diagnóstico clínico / Tuberculosis. Posmortem diagnosis and its relation with clinical diagnosis

Entre 1978 y 1991, el Hospital General ®Dr. Manuel Gea González¼ de la Secretaría de Salud, se realizaron 2,525 autopsias, encontrándose que en 66 casos (2.6 por ciento) se estableció el diagnóstico postmortem de tuberculosis, de los cuales solamente 30 de ellos contaban con diagnóstico clínico de la enfermedad. La proporción de casos diagnosticados postmortem fue mayor en hombres y se incrementó con la edad. Más del 60 por ciento de los casos de tuberculosis diseminada pasaron inadvertidos al diagnóstico clínico. Estos datos indican que la tuberculosis continúa siendo un problema subestimado clínicamente, particularmente en los pacientes de mayor edad y en aquellos con manifestaciones atípicas o extrapulmonares de la enfermedad

Pancreatitis aguda: experiencia en el Hospital General Dr. Manuel Gea González / Acute pancreatitis: experience in the Hospital General Dr. Manuel Gea Gonzalez

La pancreatitis aguda es una enfermedad con elevada prevalencia en nuestro medio, la cual provoca complicaciones que pueden desencadenar la muerte del paciente que la padece. En el presente estudio, en 2 años obtuvimos una muestra de 83 pacientes a los que observamos en forma prospectiva, estableciendo el comportamiento de la enfermedad en cada uno encontrando resultados importantes, los cuales concuerdan con los reportes a nivel mundial